Concerns related to hepatotoxicity frequently lead to discontinuation or non-initiation of HMG-coA reductase therapy in patients with cirrhosis despite data supporting statin use. We aimed to investigate the independent effects of hyperlipidemia and statin exposure on mortality, hepatic decompensation, and hepatocellular carcinoma development in a large national cohort of patients with cirrhosis.